Status:
UNKNOWN
Atrial Fibrillation in Patients Receiving Ibrutinib
Lead Sponsor:
European Georges Pompidou Hospital
Conditions:
Leukemia, Chronic Lymphatic
Mantle Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-...
Eligibility Criteria
Inclusion
- All patients deem to start ibrutinib therapy
Exclusion
- Past history of ibrutinib therapy
Key Trial Info
Start Date :
May 21 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04407845
Start Date
May 21 2020
End Date
November 30 2022
Last Update
June 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Paris, France, 75015